Organization
Janssen (A Pharmaceutical Company of Johnson & Johnson), Montclair, NJ
1 abstract
Abstract
A phase 1 study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD), and to determine the recommended phase 2 dose (RP2D) of subcutaneous (SC) cetrelimab (CET) in patients (pts) with advanced solid malignancies.Org: Medical Oncology, START Madrid-FJD, University Hospital Fundación Jiménez Diaz, Madrid, Spain, Gregorio Marañón University General Hospital, Madrid, Spain, Newcastle University, Newcastle upon Tyne, United Kingdom, Janssen Research & Development LLC, Titusville, NJ, Janssen (A Pharmaceutical Company of Johnson & Johnson), Montclair, NJ,